Abstract
A 2-yr. study was begun to evaluate the use of FTW-RBC in preventing TA-CMVI and the severity of TA-CMVI in neonates. Neonates weighing 2 kg or less were randomized to receive either liquid-stored RBC (RBC) (Gr.I) or FTW-RBC (Gr.II). CMV antibody was measured in sera from mothers and neonates (pre- and 2 mo. post-Tx). Viral cultures were done every 2 wk. 296/853 (35%) donors were seropositive (CMV Ab+). Of 71 infants analysed, 41/45 (91%) in Gr.I and 20/26 (77%) in Gr.II received CMV Ab+ blood at least once. No infant in either group receiving seronegative (CMV Ab-) blood developed TA-CMVI. The incidence of TA-CMVI in infants receiving CMV Ab+ RBC in Gr.I was 24.4% (10/41); 2/10 were born to CMV Ab+ mothers. In Gr.II, one infant seroconverted prior to Tx of CMV Ab+ FTW-RBC, suggesting nursery-acquired CMVI (NA-CMVI). In Gr.I, the mean number of Tx (19.2 vs 11.2, p<0.02) and donor exposures (12.8 vs 7.1, p<0.01) were significantly higher in infants with TA-CMVI than in CMV Ab- infants. In Gr.II, no infant, including the one with NA-CMVI, acquired TA-CMVI despite receiving the same mean number of CMV Ab+ blood Tx as did Gr.I infants. This suggests cryopreservation prevents TA-CMVI. As to severity, 1/10 infants with TA-CMVI developed hepatitis and recovered uneventfully; none died. Our preliminary data support the concept that the use of FTW-RBC or CMV Ab- RBC prevents TA-CMVI, although TA-CMVI appeared to be mild in the neonates studied.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, H., Spitzer, A. & Plotkin, S. A PROSPECTIVE STUDY OF THE USE OF FROZEN-THAWED WASHED RED BLOOD CELLS (FTW-RBC) TO PREVENT TRANSFUSION-ACQUIRED CMV INFECTION (TA-CMVI) IN THE NEONATE. Pediatr Res 18 (Suppl 4), 330 (1984). https://doi.org/10.1203/00006450-198404001-01420
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-01420